Clinical trials: Toripalimab
Advanced Malignancies
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
The primary objective is to assess the safety and tolerability of Toripalimab in subjects with various advanced malignancies and to evaluate the recommended Phase 2 dose.
- Trial name
- NCT03474640
- Testing
- Part A, Part B
- Where
- 14 sites in United States
- Volunteers
- 184 people
- Sponsor
- TopAlliance Biosciences
Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy
Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma
This is one randomized, double-blind, multi-center, placebo-controlled phase III study. The objective of this study is to compare the effectiveness and safety of JS001 combined with paclitaxel and cisplatin(TP regimen )with…
- Trial name
- JUPITER06 (NCT03829969)
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 514 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Recurrent or Metastatic NPC
The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer
This is a randomized, placebo-controlled, multi-center, double blinded, Phase III study to determine the efficacy and safety of TORIPALIMAB INJECTIO（JS001） in combination with gemcitabine/cisplatin compared with placebo in…
- Trial name
- NCT03581786
- Testing
- TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy
- Where
- 32 sites in China, Singapore and 1 more
- Volunteers
- 289 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.